HF
HCWB icon

HRT Financial’s HCW Biologics HCWB Stock Holding History

HRT Financial’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95K Buy
+44,399
New +$230K ﹤0.01% 3361
2024
Q4 		– Sell
-194
Closed -$25K – 2720
2024
Q3 		$25K Sell
194
-84
-30% -$11.4K ﹤0.01% 2169
2024
Q2 		$43K Sell
278
-27
-9% -$7.98K ﹤0.01% 1852
2024
Q1 		$122K Buy
+305
New +$97.5K ﹤0.01% 1842

Other funds holding HCWB

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

HRT Financial's HCWB Position: Q1 2026 in Review

HRT Financial opened a new position in HCW Biologics (HCWB) in Q1 2026: 44,399 shares worth $95K. The stake represents ﹤0.01% of the portfolio and ranks #3361 among its holdings. This is a return to the name: HRT Financial previously reported a position in HCWB as recently as Q3 2024.

HRT Financial first reported a position in HCWB in Q1 2024 and has held it in 4 quarters since. The position peaked at $122K in Q1 2024. 13 funds tracked by Wall St. Rank hold HCWB as of Q1 2026.

  • HRT Financial held 44,399 shares of HCW Biologics worth $95K as of Q1 2026.
  • HCW Biologics was a new HRT Financial position in Q1 2026.
  • HCW Biologics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3361 holding.
  • HRT Financial first reported a position in HCW Biologics in Q1 2024 and has held it in 4 quarters since.
  • HRT Financial's HCW Biologics position peaked at $122K in Q1 2024.
  • 13 funds tracked by Wall St. Rank held HCW Biologics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.